Cargando…

Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology

COVID-19 caused by the SARS-CoV-2 virus is widespread in all regions, and it disturbs host immune system functioning leading to extreme inflammatory reaction and hyperactivation of the immune response. Kabasura Kudineer (KSK) is preventive medicine against viral infections and a potent immune booste...

Descripción completa

Detalles Bibliográficos
Autores principales: V., Vidhya Rajalakshmi, Ramu, Akilandeswari, Chinnappan, Jayaprakash, Velmurugan, Palanivel, Pathak, Rajiv, Pashameah, Rami Adel, A. Oyouni, Atif Abdulwahab, M. Al-Amer, Osama, I. Alasseiri, Mohammed, Hamadi, Abdullah, A. Alanazi, Mansuor, Sathiamoorthi, Thangavelu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057793/
https://www.ncbi.nlm.nih.gov/pubmed/36989283
http://dx.doi.org/10.1371/journal.pone.0282263
_version_ 1785016458576658432
author V., Vidhya Rajalakshmi
Ramu, Akilandeswari
Chinnappan, Jayaprakash
Velmurugan, Palanivel
Pathak, Rajiv
Pashameah, Rami Adel
A. Oyouni, Atif Abdulwahab
M. Al-Amer, Osama
I. Alasseiri, Mohammed
Hamadi, Abdullah
A. Alanazi, Mansuor
Sathiamoorthi, Thangavelu
author_facet V., Vidhya Rajalakshmi
Ramu, Akilandeswari
Chinnappan, Jayaprakash
Velmurugan, Palanivel
Pathak, Rajiv
Pashameah, Rami Adel
A. Oyouni, Atif Abdulwahab
M. Al-Amer, Osama
I. Alasseiri, Mohammed
Hamadi, Abdullah
A. Alanazi, Mansuor
Sathiamoorthi, Thangavelu
author_sort V., Vidhya Rajalakshmi
collection PubMed
description COVID-19 caused by the SARS-CoV-2 virus is widespread in all regions, and it disturbs host immune system functioning leading to extreme inflammatory reaction and hyperactivation of the immune response. Kabasura Kudineer (KSK) is preventive medicine against viral infections and a potent immune booster for inflammation-related diseases. We hypothesize that KSK and KSK similar plant compounds, might prevent or control the COVID-19 infection in the human body. 1,207 KSK and KSK similar compounds were listed and screened via the Swiss ADME tool and PAINS Remover; 303 compounds were filtered including active and similar drug compounds. The targets were retrieved from similar drugs of the active compounds of KSK. Finally, 573 genes were listed after several screening steps. Next, network analysis was performed to finalize the potential target gene: construction of protein-protein interaction of 573 genes using STRING, identifying top hub genes in Cytoscape plug-ins (MCODE and cytoHubba). These ten hub genes play a crucial role in the inflammatory response. Target-miRNA interaction was also constructed using the miRNet tool to interpret miRNAs of the target genes and their functions. Functional annotation was done via DAVID to gain a complete insight into the mechanism of the enriched pathways and other diseases related to the given target genes. In Molecular Docking analysis, IL10 attained top rank in Target-miRNA interaction and also the gene formed prominent exchanges with an excellent binding score (> = -8.0) against 19 compounds. Among them, Guggulsterone has an acute affinity score of -8.8 for IL10 and exhibits anti-inflammatory and immunomodulatory properties. Molecular Dynamics simulation study also performed for IL10 and the interacting ligand compounds using GROMACS. Finally, Guggulsterone will be recommended to enhance immunity against several inflammatory diseases, including COVID19.
format Online
Article
Text
id pubmed-10057793
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-100577932023-03-30 Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology V., Vidhya Rajalakshmi Ramu, Akilandeswari Chinnappan, Jayaprakash Velmurugan, Palanivel Pathak, Rajiv Pashameah, Rami Adel A. Oyouni, Atif Abdulwahab M. Al-Amer, Osama I. Alasseiri, Mohammed Hamadi, Abdullah A. Alanazi, Mansuor Sathiamoorthi, Thangavelu PLoS One Research Article COVID-19 caused by the SARS-CoV-2 virus is widespread in all regions, and it disturbs host immune system functioning leading to extreme inflammatory reaction and hyperactivation of the immune response. Kabasura Kudineer (KSK) is preventive medicine against viral infections and a potent immune booster for inflammation-related diseases. We hypothesize that KSK and KSK similar plant compounds, might prevent or control the COVID-19 infection in the human body. 1,207 KSK and KSK similar compounds were listed and screened via the Swiss ADME tool and PAINS Remover; 303 compounds were filtered including active and similar drug compounds. The targets were retrieved from similar drugs of the active compounds of KSK. Finally, 573 genes were listed after several screening steps. Next, network analysis was performed to finalize the potential target gene: construction of protein-protein interaction of 573 genes using STRING, identifying top hub genes in Cytoscape plug-ins (MCODE and cytoHubba). These ten hub genes play a crucial role in the inflammatory response. Target-miRNA interaction was also constructed using the miRNet tool to interpret miRNAs of the target genes and their functions. Functional annotation was done via DAVID to gain a complete insight into the mechanism of the enriched pathways and other diseases related to the given target genes. In Molecular Docking analysis, IL10 attained top rank in Target-miRNA interaction and also the gene formed prominent exchanges with an excellent binding score (> = -8.0) against 19 compounds. Among them, Guggulsterone has an acute affinity score of -8.8 for IL10 and exhibits anti-inflammatory and immunomodulatory properties. Molecular Dynamics simulation study also performed for IL10 and the interacting ligand compounds using GROMACS. Finally, Guggulsterone will be recommended to enhance immunity against several inflammatory diseases, including COVID19. Public Library of Science 2023-03-29 /pmc/articles/PMC10057793/ /pubmed/36989283 http://dx.doi.org/10.1371/journal.pone.0282263 Text en © 2023 V. et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
V., Vidhya Rajalakshmi
Ramu, Akilandeswari
Chinnappan, Jayaprakash
Velmurugan, Palanivel
Pathak, Rajiv
Pashameah, Rami Adel
A. Oyouni, Atif Abdulwahab
M. Al-Amer, Osama
I. Alasseiri, Mohammed
Hamadi, Abdullah
A. Alanazi, Mansuor
Sathiamoorthi, Thangavelu
Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology
title Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology
title_full Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology
title_fullStr Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology
title_full_unstemmed Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology
title_short Interleukin-10 as Covid-19 biomarker targeting KSK and its analogues: Integrated network pharmacology
title_sort interleukin-10 as covid-19 biomarker targeting ksk and its analogues: integrated network pharmacology
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057793/
https://www.ncbi.nlm.nih.gov/pubmed/36989283
http://dx.doi.org/10.1371/journal.pone.0282263
work_keys_str_mv AT vvidhyarajalakshmi interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT ramuakilandeswari interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT chinnappanjayaprakash interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT velmuruganpalanivel interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT pathakrajiv interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT pashameahramiadel interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT aoyouniatifabdulwahab interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT malamerosama interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT ialasseirimohammed interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT hamadiabdullah interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT aalanazimansuor interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology
AT sathiamoorthithangavelu interleukin10ascovid19biomarkertargetingkskanditsanaloguesintegratednetworkpharmacology